CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

Status Active, not recruiting

Clinical Trial Summary

In this phase I study, the investigators will first evaluate the safety of CAR20.19.22 T-cells in patients with B-cell non-Hodgkin lymphoma (NHL) / chronic lymphocytic leukemia (CLL).

Clinical Trial Description

This is a phase I, interventional, open label, dose-finding treatment study designed to evaluate the safety and efficacy CAR20.19.22 T-cells in adult patients with B-cell malignancies that have failed prior therapies. ;

Study Design

Related Conditions & MeSH terms

B-cell Chronic Lymphocytic Leukemia
B-cell Non Hodgkin Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin

Clinical Trial Details

NCT number	NCT05094206
Study type	Interventional
Source	Medical College of Wisconsin
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	June 30, 2022
Completion date	February 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03204188` - Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Phase 2
Terminated	`NCT00377104` - Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Phase 1
Completed	`NCT00006226` - Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia	Phase 2
Completed	`NCT01576588` - Rituximab in Pretreated Elderly or Unfit B-CLL Patients	Phase 2
Completed	`NCT01212380` - Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)	Phase 1
Terminated	`NCT00288067` - Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Phase 1/Phase 2
Completed	`NCT00098670` - Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia	Phase 2
Completed	`NCT00910910` - Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)	Phase 3
Recruiting	`NCT03110640` - Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma	Phase 1
Terminated	`NCT00101205` - Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma	Phase 1
Completed	`NCT00005799` - Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	N/A
Terminated	`NCT02440685` - A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT01105247` - Safety of PCI-32765 in Chronic Lymphocytic Leukemia	Phase 1/Phase 2
Terminated	`NCT01126502` - Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia	Phase 1
Completed	`NCT00321724` - AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia	Phase 2
Completed	`NCT02381080` - Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy	Phase 1
Completed	`NCT04030195` - Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL	Phase 1/Phase 2
Withdrawn	`NCT00918450` - Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen	Phase 2
Terminated	`NCT00302861` - A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL)	Phase 1/Phase 2
Completed	`NCT00290472` - CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	Phase 2